Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEBS (P. falciparum Pre-Erythrocytic and Blood Stage) is a first-generation protein subunit vaccine developed by Vac4All targeting the Liver-Stage Antigen-5 (LSA5) for protection against *Plasmodium falciparum* malaria. The vaccine is designed to induce immunity against both the liver (pre-erythrocytic) and blood (asexual) stages of the malaria parasite. It is manufactured as a synthetic protein of 131 amino acids and is adjuvanted with aluminum hydroxide. Clinical testing in Phase 1/2a trials demonstrated safety in humans, although the immune responses were considered unsatisfactory, likely due to inadequate adjuvantation. This has led to the development of second-generation candidates, such as LSA5 Biofusion, which aim to improve upon the first-generation prototype.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PEBS.